Noriko Shimasaki Selected Research

Antigens

1/2016	Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation.
1/2013	Natural killer cell reprogramming with chimeric immune receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Noriko Shimasaki Research Topics

Disease

14	Neoplasms (Cancer) 09/2022 - 02/2004
4	Leukemia 01/2020 - 05/2009
3	Lymphoma (Lymphomas) 01/2020 - 02/2006
3	Infections 01/2018 - 01/2016
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2009 - 02/2006
2	Hepatocellular Carcinoma (Hepatoma) 01/2016 - 08/2013
1	Exanthema (Rash) 09/2022
1	Nasopharyngeal Carcinoma 09/2022
1	Hepatitis B 02/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2017
1	Communicable Diseases (Infectious Diseases) 09/2016
1	Melanoma (Melanoma, Malignant) 01/2016
1	Cross Infection (Nosocomial Infection) 01/2016
1	Experimental Arthritis 04/2011
1	Arthritis (Polyarthritis) 04/2011
1	Inflammation (Inflammations) 04/2011
1	Rheumatoid Arthritis 04/2011
1	Osteosarcoma (Osteogenic Sarcoma) 08/2010
1	Ewing Sarcoma (Sarcoma, Ewing) 08/2010
1	Rhabdomyosarcoma 08/2010
1	Neuroblastoma 08/2010
1	Mucositis 02/2006
1	Vomiting 02/2006
1	Genomic Instability 10/2004
1	Chromosome Aberrations (Chromosome Abnormalities) 10/2004
1	Intussusception 05/2004
1	Pneumatosis Cystoides Intestinalis 05/2004
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 02/2004

Drug/Important Bio-Agent (IBA)

6	Chimeric Antigen ReceptorsIBA 01/2022 - 08/2012
4	Methotrexate (Mexate)FDA LinkGeneric 04/2011 - 02/2006
2	AerosolsIBA 01/2018 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 08/2013
2	AntigensIBA 01/2016 - 01/2013
2	LigandsIBA 08/2010 - 05/2009
2	Reduced Folate Carrier ProteinIBA 05/2008 - 02/2006
2	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 05/2008 - 02/2006
1	Cetuximab (Erbitux)FDA Link 09/2022
1	ErbB Receptors (EGF Receptor)IBA 09/2022
1	niranthinIBA 02/2022
1	LignansIBA 02/2022
1	CyclopropanesIBA 02/2022
1	Bevacizumab (Avastin)FDA Link 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	Hazardous Substances (Hazardous Materials)IBA 01/2018
1	Interleukin-15 (Interleukin 15)IBA 05/2017
1	4-1BB Ligand (4 1BB Ligand)IBA 05/2017
1	AntibodiesIBA 09/2016
1	Peptides (Polypeptides)IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016
1	Messenger RNA (mRNA)IBA 04/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2011
1	Pharmaceutical PreparationsIBA 04/2011
1	InterleukinsIBA 05/2009
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 05/2008
1	MutagensIBA 10/2004
1	Rituximab (Mabthera)FDA Link 02/2004

Therapy/Procedure

7	Therapeutics 09/2022 - 05/2009
5	Immunotherapy 01/2020 - 05/2009
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2016 - 05/2009
2	Protective Clothing 01/2018 - 01/2016
2	Cord Blood Stem Cell Transplantation 05/2004 - 02/2004
1	Drug Therapy (Chemotherapy) 11/2017
1	Blood Component Removal (Apheresis) 11/2016
1	Chronotherapy 04/2011
1	Maintenance Chemotherapy 05/2008